Peter I Croucher

Peter I Croucher

UNVERIFIED PROFILE

Are you Peter I Croucher?   Register this Author

Register author
Peter I Croucher

Peter I Croucher

Publications by authors named "Peter I Croucher"

Are you Peter I Croucher?   Register this Author

74Publications

1708Reads

7Profile Views

PYY is a negative regulator of bone mass and strength.

Bone 2019 Oct 12;127:427-435. Epub 2019 Jul 12.

Molecular Endocrinology Laboratory, Department of Medicine, Hammersmith Campus, Imperial College London, London W12 0NN, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2019.07.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715792PMC
October 2019

Loss of the Vitamin D Receptor in Human Breast Cancer Cells Promotes Epithelial to Mesenchymal Cell Transition and Skeletal Colonization.

J Bone Miner Res 2019 Sep 25;34(9):1721-1732. Epub 2019 Jun 25.

Bone Research Program, ANZAC Research Institute and Concord Medical School, The University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.3744DOI Listing
September 2019

A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD-Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis.

J Bone Miner Res 2019 Sep 16. Epub 2019 Sep 16.

Faculty of Health, Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Translational Research Institute, Princess Alexandra Hospital, Woolloongabba, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.3875DOI Listing
September 2019

Cancer Cell Dormancy in Metastasis.

Cold Spring Harb Perspect Med 2019 Sep 23. Epub 2019 Sep 23.

Bone Biology, The Garvan Institute of Medical Research, Sydney 2010 NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a037556DOI Listing
September 2019

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.

Neoplasia 2019 08 24;21(8):777-787. Epub 2019 Jun 24.

Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Terrace, Adelaide, 5005; Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, 5001; Centre for Cancer Biology, University of South Australia and SA Pathology, PO Box 2471, Adelaide, 5001. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2019.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593350PMC
August 2019

Genome-wide association study of extreme high bone mass: Contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes.

Bone 2018 09 5;114:62-71. Epub 2018 Jun 5.

Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology at Translational Research Institute, 37 Kent Street, Woolloongabba 4102, QLD, Australia; Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S87563282183022
Publisher Site
http://dx.doi.org/10.1016/j.bone.2018.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086337PMC
September 2018

Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer.

Int J Mol Sci 2018 Sep 26;19(10). Epub 2018 Sep 26.

Department of Oncology and Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield S10 2RX, UK.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/19/10/2920
Publisher Site
http://dx.doi.org/10.3390/ijms19102920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213905PMC
September 2018

Single Cell RNA Sequencing of Rare Immune Cell Populations.

Front Immunol 2018 4;9:1553. Epub 2018 Jul 4.

Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.01553
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.01553DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039576PMC
July 2018

Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation.

Calcif Tissue Int 2018 01 6;102(1):105-116. Epub 2017 Nov 6.

Orthopaedic Research & Biotechnology Unit, The Children's Hospital at Westmead, Research Building, Locked Bag 4001, Westmead, NSW, 2145, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00223-017-0338-4
Publisher Site
http://dx.doi.org/10.1007/s00223-017-0338-4DOI Listing
January 2018

Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.

Am J Hum Genet 2018 01;102(1):88-102

Department of Internal Medicine, Erasmus MC, 3000 CA Rotterdam, the Netherlands; The Generation R Study Group, Erasmus MC, 3000 CA Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, 3000 CA Rotterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajhg.2017.12.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777980PMC
January 2018

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.

Neoplasia 2017 Dec 5;19(12):972-981. Epub 2017 Nov 5.

Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, 5000, Australia; South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678743PMC
December 2017

HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.

Cancer Res 2017 10 30;77(20):5452-5463. Epub 2017 Aug 30.

Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0115DOI Listing
October 2017

An Essential Physiological Role for MCT8 in Bone in Male Mice.

Endocrinology 2017 09;158(9):3055-3066

Molecular Endocrinology Laboratory, Department of Medicine, Hammersmith Campus, Imperial College London, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2017-00399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659673PMC
September 2017

Next generation mapping reveals novel large genomic rearrangements in prostate cancer.

Oncotarget 2017 Apr;8(14):23588-23602

Laboratory for Human Comparative and Prostate Cancer Genomics, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Darlinghurst, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410329PMC
April 2017

Rapid phenotyping of knockout mice to identify genetic determinants of bone strength.

J Endocrinol 2016 10 17;231(1):R31-46. Epub 2016 Aug 17.

Molecular Endocrinology LaboratoryDepartment of Medicine, Imperial College London, London, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/JOE-16-0258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064764PMC
October 2016

Bone metastasis: the importance of the neighbourhood.

Nat Rev Cancer 2016 05;16(6):373-86

St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, Victoria 3065, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.44DOI Listing
May 2016

N-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse models.

PLoS One 2015 10;10(4):e0122650. Epub 2015 Apr 10.

Academic Endocrine Unit, Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122650PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393098PMC
March 2016

The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer.

J Exp Clin Cancer Res 2015 Oct 20;34:124. Epub 2015 Oct 20.

The Mellanby Centre for Bone Research, Department of Human Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-015-0240-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615337PMC
October 2015

Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development.

Endocrinology 2015 09 27;156(9):3098-113. Epub 2015 May 27.

Molecular Endocrinology Laboratory (J.H.D.B., J.G.L., A.G., J.B.C., E.M., G.R.W.), Department of Medicine, Imperial College London, London, W12 0NN United Kingdom; Department of Endocrinology (A.v.d.S., C.v.Z., A.Boe.), Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands; Bone Biology Program (J.D., P.I.C.), Garvan Institute of Medical Research, Sydney, NSW 2010 Australia; and Centre for Oral Growth and Development (A.Boy.), Queen Mary, University of London, London, E1 4NS United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2014-1943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541616PMC
September 2015

OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.

Int J Cancer 2015 Aug 2;137(4):968-77. Epub 2015 Feb 2.

Department of Oncology, Academic Unit of Clinical Oncology, University of Sheffield, S10 2RX, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.29439
Publisher Site
http://dx.doi.org/10.1002/ijc.29439DOI Listing
August 2015

Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.

FASEB J 2015 Aug 17;29(8):3141-50. Epub 2015 Apr 17.

*Department of Human Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom; Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, Manchester, United Kingdom; Department of Oncology, Medical School, University of Sheffield, Sheffield, United Kingdom; and Bone Biology Division, Garvan Institute of Medical Research, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.14-266379DOI Listing
August 2015

Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?

Eur Urol 2015 Jul 11;68(1):51-2. Epub 2014 Nov 11.

Garvan Institute of Medical Research, Darlinghurst, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.10.041DOI Listing
July 2015

Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.

J Bone Miner Res 2014 Dec;29(12):2688-96

The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Sheffield, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jbmr.2300
Publisher Site
http://dx.doi.org/10.1002/jbmr.2300DOI Listing
December 2014

Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

Endocr Relat Cancer 2014 Oct 22;21(5):769-81. Epub 2014 Jul 22.

Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0199DOI Listing
October 2014

Thyroid hormone receptor α mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.

Endocrinology 2014 Sep 10;155(9):3699-712. Epub 2014 Jun 10.

Department of Medicine (J.H.D.B., G.R.W.), Imperial College London, London W12 0NN, United Kingdom; Dental Physical Sciences, Oral Growth and Development (A.B.), Queen Mary University of London, London E1 4NS, United Kingdom; Laboratory of X-Ray Micro-Computed Tomography and Nano-Computed Tomography (T.Z.), Central European Institute of Technology, Brno University of Technology CZ-61600 Brno, Czech Republic; Sheffield Myeloma Research Team (H.E.), University of Sheffield, Sheffield S10 2RX, United Kingdom; Bone Biology Program (P.I.C.), Garvan Institute of Medical Research, Sydney NSW 2010, Australia; and Laboratory of Molecular Biology (X.Z., J.W.P., S-y.C.), National Cancer Institute, Bethesda, Maryland 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2013-2156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138578PMC
September 2014

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

Clin Cancer Res 2014 Jun 31;20(11):2922-32. Epub 2014 Mar 31.

Authors' Affiliations: Academic Unit of Clinical Oncology, Department of Oncology, Academic Unit of Bone Biology, Department of Human Metabolism, University of Sheffield, Sheffield, United Kingdom; and Musculoskeletal Medicine Division, Garvan Institute of Medical Research, Sidney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040234PMC
June 2014

An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.

Endocrinology 2014 Mar 3;155(3):908-22. Epub 2013 Dec 3.

Mammalian Genetics Unit (L.B., C.T.E., R.A.H., S.D.M.B., R.D.C.) and Mary Lyon Centre (C.L.S., T.A.H.), Medical Research Council Harwell, Harwell Science and Innovation Campus, Oxfordshire OX11 0RD, United Kingdom; Academic Endocrine Unit (C.T.E., M.A.N., R.A.H., F.M.H., R.V.T.), Nuffield Department of Clinical Medicine, University of Oxford, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford OX3 7LE, United Kingdom; The Mellanby Centre for Bone Research (H.E., D.L.), Department of Human Metabolism, University of Sheffield, Sheffield S10 2RX, United Kingdom; Wellcome Trust Sanger Institute (C.P.), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, United Kingdom; Norwich Medical School (W.D.F.), University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United Kingdom; Garvan Institute of Medical Research (P.I.C.), Musculoskeletal Medicine Division, University of New South Wales, Sydney 2010, Australia; and University of Queensland Diamantina Institute (M.A.B.), Princess Alexandra Hospital, University of Queensland, Brisbane 4102, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2013-1247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192286PMC
March 2014

Signaling between tumor cells and the host bone marrow microenvironment.

Calcif Tissue Int 2014 Jan 18;94(1):125-39. Epub 2013 Sep 18.

Bone Biology Group, Musculoskeletal Division, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00223-013-9794-7DOI Listing
January 2014

Bone Mineral Content and Density.

Curr Protoc Mouse Biol 2012 Dec 1;2(4):365-400. Epub 2012 Dec 1.

Academic Endocrine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/9780470942390.mo120124DOI Listing
December 2012

Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.

PLoS One 2012 16;7(5):e35830. Epub 2012 May 16.

The Mellanby Centre for Bone Research, Department of Human Metabolism, University of Sheffield Medical School, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035830PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353958PMC
September 2012

A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation.

J Bone Miner Res 2012 Feb;27(2):413-28

Academic Endocrine Unit, Nuffield Department of Clinical Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.547DOI Listing
February 2012

Bisphosphonates in preclinical bone oncology.

Bone 2011 Jul 8;49(1):66-70. Epub 2010 Dec 8.

INSERM, UMR, IFR, Lyon, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S87563282100204
Publisher Site
http://dx.doi.org/10.1016/j.bone.2010.11.017DOI Listing
July 2011

Tumor-host cell interactions in the bone disease of myeloma.

Bone 2011 Jan 13;48(1):121-8. Epub 2010 Jul 13.

Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2010.06.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005983PMC
January 2011

Metastasis and bone loss: advancing treatment and prevention.

Cancer Treat Rev 2010 Dec 15;36(8):615-20. Epub 2010 May 15.

Yorkshire Cancer Research Professor of Medical Oncology, Academic Unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S102SJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2010.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047387PMC
December 2010

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

J Bone Miner Res 2009 Mar;24(3):425-36

Academic Unit of Bone Biology, Section of Musculoskeletal Sciences, University of Sheffield School of Medicine and Biomedical Sciences, Sheffield, Yorkshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1359/jbmr.081104DOI Listing
March 2009

Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.

Biochem Biophys Res Commun 2008 Dec 16;377(2):453-457. Epub 2008 Oct 16.

Academic Unit of Bone Biology, University of Sheffield, School of Medicine and Biomedical Science, Beech Hill Road, Sheffield S10 2RX, UK. Electronic address:

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0006291X0801944
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2008.09.157DOI Listing
December 2008

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.

J Biol Chem 2007 Oct 15;282(43):31601-9. Epub 2007 Aug 15.

Section of Musculoskeletal Science, University of Sheffield School of Medical and Biomedical Sciences, Beech Hill Road, Sheffield, Yorkshire S10 2RX, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M706078200DOI Listing
October 2007

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Int J Cancer 2007 Apr;120(8):1657-63

Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.22478DOI Listing
April 2007

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

Cancer Res 2007 Jan;67(1):202-8

Academic Unit of Bone Biology, Division of Clinical Sciences (South), University of Sheffield Medical School, Beech Hill Road, Sheffield, Yorkshire, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-1287DOI Listing
January 2007

Evidence of a role for RANKL in the development of myeloma bone disease.

Curr Opin Pharmacol 2004 Aug;4(4):340-6

Bone Biology Group, G Floor, Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2004.03.011DOI Listing
August 2004

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Prostate 2004 May;59(3):304-10

Academic Urology Unit, University of Sheffield Medical School, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20016DOI Listing
May 2004

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

Cancer Res 2003 Mar;63(5):912-6

Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford OX3 7LD, United Kingdom.

View Article

Download full-text PDF

Source
March 2003

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Cancer 2003 Feb;97(3 Suppl):818-24

Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11125DOI Listing
February 2003

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Cancer Res 2002 Mar;62(6):1619-23

Bone Oncology Group, Divisions of Clinical Sciences and Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK.

View Article

Download full-text PDF

Source
March 2002